On June 5, 2026 Nerviano Medical Sciences S.r.l. ("NMS"), a global oncology-focused biopharmaceutical company, reported its participation in the upcoming Annual Congress of the European Association for Cancer Research (EACR), taking place in Budapest, Hungary, from June 8 to 11, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
At the meeting, NMS will present a scientific poster featuring its proprietary dual PERK/GCN2 inhibitor, NMS-812.
Title: "NMS-812, a clinical stage dual PERK and GCN2 modulator, with activity in Multiple Myeloma, AML and solid tumors" (Poster EACR26-0678)
Presenter: Claudia Perrera, Head of Biology at NMS
Poster Section: "Experimental / Molecular Therapeutics, Pharmacogenomics"
Poster Board Number: P-355
Date & Time: Tuesday, 09 June 2026 from 10:30 to 20:00 CET
Link to full poster abstract: NMS POSTER SESSION – Tuesday – EACR Congress
This study presents NMS-812, a potent first-in-class clinical-stage dual PERK/GCN2 inhibitor that disrupts tumor stress-response survival pathways, demonstrating single-agent and combination antitumor activity across multiple myeloma, AML, and solid tumor models, including immune-mediated effects, supporting its ongoing Phase 1 AML development and potential expansion into solid tumors.
We look forward to engaging with the scientific community at EACR 2026 and sharing insights from our work.
(Press release, Nerviano Medical Sciences, JUN 5, 2026, View Source [SID1234666467])